Advisor across the full breadth of the Healthcare sector
Selected Healthcare Services transactions
FYEO (2026)
Sole financial adviser to Committed Capital, management and minority shareholders on the sale of FYEO to EuroEyes
Diagnostyka (2025)
Independent financial adviser to MidEuropa on the €404m IPO of Diagnostyka on the Warsaw Stock Exchange
Equine Care Group (2025)
Sole financial adviser to Bencis and shareholders on the sale of Equine care group to Compagnie Nationale à Portefeuille
Fakih IVF (2025)
Financial adviser to NMC on the disposal of a 65% stake in Fakih IVF to Blue Ocean Health
HHG and CVC (2025)
Financial adviser CVC and to Hellenic Healthcare Group on its 60% sale to Pure Health for an implied EV of c.€2.2bn
Labor Team (2025)
Sole financial adviser to GENUI on the sale of Labor Team to Galenica
mydentist (2025)
Sole financial adviser to Bridgepoint on its acquisition of mydentist from Palamon
Optegra (2025)
Sole advisor to EssilorLuxottica on the acquisition of Optegra from MidEuropa
Regina Maria Group (2025)
Sole financial adviser to MidEuropa on the sale of Regina Maria and MediGroup to Mehiläinen
Stingray Healthcare (2025)
Sole financial adviser to Jacobs Capital on the sale of Stingray to Fremman Capital
The Hakim Group (2025)
Sole financial adviser to the Hakim Family and All Seas Capital on the sale of The Hakim Group to ICG
Vitalia (2025)
Sole financial adviser to Stepstone Real Estate and Greykite on the ~€1.5bn majority acquisition and recapitalization of Vitalia from CVC and Portobello
Selected MedTech transactions
Charterhouse Capital Partners (2025)
Sole financial adviser to Charterhouse Capital Partners on their majority investment in Winback
Stago (2025)
Financial adviser to Stago on the sale of a majority stake to a consortium led by ARCHIMED
Medline (2025)
Co-manager on Medline’s upsized $6.3bn IPO on Nasdaq
Montagu & Kohlberg (2025)
Adviser to Montagu and Kohlberg on an $875m committed financing package for the $1.5bn acquisition of Teleflex Medical OEM
IGS GeboJagema (2025)
Adviser to the shareholders of IGS GeboJagema on the sale to BC Partners
Sagard (2025)
Adviser to Sagard in the context of the disposal of Sterimed to IK Partners
Ypsomed (2025)
Sole financial adviser to Ypsomed in relation to the carve-out and sale of Ypsomed Diabetes Care to TecMed for ~CHF420m
PAI Partners (2025)
Sole financial adviser to PAI Partners on the disposal of its stake in Amplitude Surgical to Zydus Lifesciences and subsequent mandatory cash tender offer
Selected Pharma Services transactions
Sandoz (2025)
Adviser to Sandoz on the acquisition of Just – Evotec Biologics EU SAS
CVC (2025)
Adviser to CVC and the Founding family on the sale of Genetic to Renaissance Partners and Aurora Growth Capital
HAS (2025)
Adviser to HAS and the Braglia Family on the acquisition of Cerbios and simultaneous sale of a minority stake to 65 Equity Partners
Synthon (2024)
Financial adviser to BC Partners on the sale of Synthon to Goldman Sachs Asset Management for an enterprise value of €2bn
Swixx BioPharma (2025)
Sole financial adviser to SK Capital on its acquisition of Swixx BioPharma at an EV in excess of €1.5bn
CapVest (2025)
Adviser to CapVest in relation to the recapitalisation of Perceptive via a new continuation vehicle with Curium at a combined EV of ~$7bn
Apex Healthcare (2025)
Sole financial adviser on the sale of a majority stake of Apex Healthcare Berhad to a consortium led by Quadria Capital
GTCR (2025)
Adviser to GTCR on the sale of Klick Health to Linden Capital Partners and GIC
CVC (2025)
Advisor to CVC and the Founding family on the sale of Genetic to Renaissance Partners and Aurora Growth Capital
SERB Pharmaceuticals (2025)
Sole financial advisor to SERB Pharmaceuticals on its $412m public tender offer on Y-mAbs Therapeutics
Inventia Healthcare (2024)
Financial advisor to the shareholders of Inventia Healthcare on the sale of a controlling stake in their core Oral Solid Dosage business to Platinum Equity
US Pharma Lab (2023)
Financial advisor to US Pharma Lab on its sale to Ardian-backed Biofarma Group
IK Partners (2024)
Financial advisor to IK Partners on the acquisition of a majority stake in Eurobio Scientific
HAS (2025)
Advisor to HAS and the Braglia Family on the acquisition of Cerbios and simultaneous sale of a minority stake to 65 Equity Partners
Synthon (2024)
Financial advisor to BC Partners on the sale of Synthon to Goldman Sachs Asset Management for an enterprise value of €2bn
Alvogen (2025)
Joint financial advisor to Alvogen, CVC and other shareholders on its sale to Lotus for an EV of up to $2.0bn
STADA (2025)
Financial advisor to Cinven and Bain Capital on the disposal of a majority stake in STADA to CapVest at an EV of c.10bn
SERB Pharmaceuticals (2025)
Sole financial advisor to SERB Pharmaceuticals on its $412m public tender offer on Y-mAbs Therapeutics
Mérieux Equity Partners (2025)
Sole financial advisor to Mérieux Equity Partners on the sale of Theravia to Norgine
Provepharm (2025)
Sole financial advisor to Provepharm on securing a US licensing agreement for its three innovative medical dyes with Sagent Pharmaceuticals
Gyrus Capital (2024)
Financial advisor to Gyrus Capital on the €584m continuation vehicle for Essential Pharma at an implied EV of ~€790m
BC Partners (2025)
Sole financial advisor to BC Partners on the acquisition of Biogaran from Servier
KKR (2025)
Advisor to KKR on controlling stake sale of JB Chemicals & Pharmaceuticals to Torrent Pharmaceuticals at an equity valuation of ~$3bn
Orifarm and Habico Invest (2024)
Sole financial advisor to Orifarm and Habico Invest on strategic capital investment by Carlyle Global Credit
Montagu Private Equity (2023)